Revisiting chemoresistance in ovarian cancer:Mechanism,biomarkers,and precision medicine

作     者：Chong Guo Chaoying Song Jiali Zhang Yisong Gao Yuying Qi Zongyao Zhao Chengfu Yuan 

作者机构：College of Medical ScienceChina Three Gorges UniversityYichangHubei 443002PR China Third-Grade Pharmacological Laboratory on Chinese Medicine Approved by State Administration of Traditional Chinese MedicineChina Three Gorges UniversityYichangHubei 443002PR China Hubei Key Laboratory of Tumor Microenvironment and ImmunotherapyChina Three Gorges UniversityYichangHubei 443002PR China 

出 版 物：《Genes & Diseases》 (基因与疾病（英文）)

年 卷 期：2022年第9卷第3期

页      面：668-681页

核心收录：

学科分类：0710[理学-生物学] 0831[工学-生物医学工程（可授工学、理学、医学学位）] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 0703[理学-化学] 10[医学] 

基　　金：This study was finandaily supported by the grants from National Natural Science Foundation of China(No.81773959 to C.F.Yuan and 81974528 to C.F.Yuan) Open Foundation for Tumor Microenvironment and Immunotherapy Key Laboratory of Hubei province in China(No.2019KZL09 to C.F.Yuan) Health commission of Hubei Province scientific research project(No.WJ2019H527 to C.F.Yuan) the central government guides the special funds for the development of local scienee and technology(No.2020ZYYD016 to C.F.Yuan). 

主　　题：Clinical outcomes Mechanisms Molecular biomarkers Ovarian cancer Platinum resistance 

摘      要：Among the gynecological cancers,ovarian cancer is the most lethal.Its therapeutic options include a combination of chemotherapy with platinum-based compounds and cytoreductive surgery.Most ovarian cancer patients exhibit an initial response to platinum-based therapy,however,platinum resistance has led to up to 80%of this responsive cohort becoming refractory.Ovarian cancer recurrence and drug resistance to current chemotherapeutic options is a global challenge.Chemo-resistance is a complex phenomenon that involves multiple genes and signal transduction pathways.Therefore,it is important to elucidate on the underlying molecular mechanisms involved in chemo-resistance.This inform decisions regarding therapeutic management and help in the identification of novel and effective drug targets.Studies have documented the individual bidmarkers of platinum-resistance in ovarian cancer that are potential therapeutic targets.This review summarizes the molecular mechanisms of platinum resistance in ovarian cancer,novel drug targets,and clinical outcomes.